TAK-583
TAK-583-EC201
Phase 3 small_molecule completed
Quick answer
TAK-583 for Neuralgia, Postherpetic is a Phase 3 program (small_molecule) at Takeda with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Takeda
- Indication
- Neuralgia, Postherpetic
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed